Brainstorm Cell Therapeutics BCLI
OTC BCLI
$0.99 +0.07 (+7.61%)
At close: Nov 10, 2026 · 4:00 PM EST

Brainstorm Cell Therapeutics (BCLI) Short term Debt (2009)

Updated

Analysis

Brainstorm Cell Therapeutics (BCLI) Short term Debt (2009) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Brainstorm Cell Therapeutics 10.92 Mn 10.85 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2009 189,000.00
Sep 30, 2009 186,000.00
Jun 30, 2009 178,000.00
Mar 31, 2009 175,000.00
API Access

Brainstorm Cell Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=BCLI&period=max&api_key=YOUR_API_KEY